Condition: Systemic Lupus Erythematosus of Childhood · Sponsor: Meyer Children's Hospital IRCCS
Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent of renal damage. In pediatric SLE, and particularly in lupus nephritis, activation of the IFN-I pathway has never been studied, nor is it known whether monogenic forms underlie more pronounced interferon activation.
This description comes directly from the study's public registry record.
Carmela Errichiello, MD · 055/5662563 · carmela.errichiello@meyer.it
Carmela Errichiello, MD · 055/5662563
Always discuss trial participation with your own doctor first.
| Meyer Children's Hospital IRCCS | Florence, Italy | Recruiting |
| IRCCS Gianna Gaslini | Genova, Italy | Recruiting |
| IRCCS Humanitas Research Hospital | Rozzano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06586710